GLP-1s and Muscle Loss: What the Evidence Shows
What body-composition studies of semaglutide and tirzepatide found about lean mass, why 'lean mass' is not the same as muscle, and what the evidence does and does not say about protecting it.
On this page
The short answer
Yes, people on semaglutide and tirzepatide in trials lost some lean mass along with fat. In a tirzepatide body-composition substudy, about 75% of the weight lost was fat and about 25% was lean mass, the same split as placebo. A review estimates that semaglutide users in STEP 1 lost at least 10% of their muscle mass. Lean mass is not all muscle, and the evidence does not show how much any one person loses. Protein and strength training are the commonly recommended responses, and your clinician can tailor them.
When is weakness a reason to get care now?
Call 911 right away for sudden numbness or weakness in the face, arm, or leg, especially on one side, or for sudden trouble walking, loss of balance, trouble speaking, trouble seeing, or a sudden severe headache. These are stroke signs, and the CDC says not to drive yourself. 5
Contact your prescriber promptly if you are weaker than usual, struggle to climb stairs or rise from a chair, fall, or cannot eat or drink enough. Do not assume it is expected, and do not assume it is muscle loss. Fatigue, low intake, dehydration, and other conditions can look the same, and only an assessment can sort them out. Our article on feeling tired on a GLP-1 covers what to bring to that conversation.
The rest of this page explains what studies measured. It cannot tell you whether you are losing muscle.
How much lean mass did people lose in the trials?
Some, in proportion to the weight they lost. In a SURMOUNT-1 substudy of 160 people who had DXA scans at baseline and week 72, tirzepatide lowered body weight by 21.3%, fat mass by 33.9%, and lean mass by 10.9%. Placebo lowered them by 5.3%, 8.2%, and 2.6%. About 75% of the weight lost was fat and 25% was lean mass, for both tirzepatide and placebo. 1
A review of the semaglutide STEP 1 trial reports a different split. Its DXA subset lost 6.92 kg of lean mass, 13.2% of baseline lean mass and about 40% of the weight lost. 2
| Tirzepatide (SURMOUNT-1 DXA substudy) | Semaglutide (STEP 1 DXA subset, as reported in a review) | |
|---|---|---|
| People with DXA data | 160 (124 on tirzepatide, 36 on placebo) | Subset; size not stated in the review |
| Length | 72 weeks | 68 weeks |
| Lean mass change | −10.9% | −13.2% (6.92 kg) |
| Share of weight lost that was lean mass | About 25% | About 40% |
Do not read the table as one drug protecting muscle better than the other. The studies differ in design, people, and how they were reported, and neither was built to compare the drugs. Different counts and different proportions are what the sources report, not a verdict. 1 2
Is lean mass the same as muscle?
No. DXA lean mass is fat-free mass minus bone mineral content. It includes muscle, organs, and water. 1 The review notes that muscle usually makes up about half of lean mass, that the STEP 1 publication cannot show how much of the loss was muscle, and that its estimate of at least 10% muscle loss is a "conservative estimate" built on assumptions. 2
So the plain answer is that muscle probably fell, but the trials did not measure by how much. Neither source reports that people lost strength or function in daily life. The review also notes that many studies do not describe their DXA methods in enough detail to know what compartment was measured. 2
Why does this matter more after 40?
Muscle mass declines gradually with age, and the SURMOUNT-1 authors note this can lead to sarcopenia, a loss of muscle function and mass. 1 The review adds that women are already at higher risk of sarcopenia and sarcopenic obesity, which is excess body fat alongside low muscle mass or function. 2
The SURMOUNT-1 substudy found the fat-to-lean proportion "relatively consistent" across subgroups, including by sex and age under 50 versus older. The authors caution that the subgroups were small and the analyses post hoc, so no conclusion about any one group should be drawn. 1 The evidence does not show that women over 40 lose a larger share than anyone else. It shows they have more reason to ask. Our piece on GLP-1s after menopause covers bone as well as muscle.
What do nutrition and obesity organizations recommend?
The Obesity Society's advisory lists "muscle and bone loss" among challenges GLP-1 medicines can present, and lists adequate protein intake and strength training to preserve lean mass among its nutritional priorities. It gives no protein target. 3
The review is more specific: it recommends monitoring protein intake, notes the general adult recommended allowance is 0.8 g per kg of body weight daily and that other guidelines suggest higher amounts in some groups, and says intake should be adapted to the individual. It also states that resistance training "has been shown to effectively minimize loss of muscle mass and function" during weight reduction. 2 That is a recommendation from a review and a position statement. It is not a guarantee that either habit prevents loss for you.
The CDC's general adult guidance is muscle-strengthening activity on 2 days a week, covering all major muscle groups. 4 That is a general benchmark, not a plan built around your joints, medicines, or conditions. For food ideas that work with a smaller appetite, see protein meals for a smaller appetite and our GLP-1 meal guide.
What can you ask your clinician?
Use this checklist at your next visit. Nothing here replaces an individual assessment.
| Question | Why it is worth asking |
|---|---|
| How much protein is right for me, given my kidneys and other conditions? | Targets are individual, and the sources give general ranges only. |
| Should I see a dietitian? | The review recommends dietitian support where available. 2 |
| What strength activity is safe given my joints, bones, and history? | General guidance does not account for your health. 4 |
| Is any of my tiredness or weakness something to check, not assume? | Several causes look alike. |
| Is a body-composition scan useful for me? | The trials used DXA, but whether routine scans change care is not established in these sources. |
| What would make you want to reassess my plan? | You leave with a threshold, not a worry. |
Common questions
Does everyone on a GLP-1 lose muscle?
The trials report average changes in groups. They do not say what happens to any one person, and the sources cannot tell you whether you will lose muscle. 1
Does eating more protein prevent muscle loss?
The sources recommend adequate protein and describe it as important, but they do not show that protein alone prevents the loss. 2 3
Is the weight lost from placebo also lean mass?
Yes. In SURMOUNT-1, the placebo group also lost lean mass, and about the same share of its weight loss was lean. Losing weight by any route tends to reduce some lean mass. 1
References
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight — Diabetes, Obesity and Metabolism
- Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity — Obesity Reviews
- Nutritional Priorities to Support GLP-1 Therapy for Obesity — The Obesity Society
- Adult Activity: An Overview — Centers for Disease Control and Prevention
- Stroke Signs and Symptoms — Centers for Disease Control and Prevention
For your information. This article provides general education and does not replace medical advice or an individual evaluation. Talk to your clinician before starting, changing, or stopping treatment. Compounded medications are not FDA-approved.